{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T06:13:16Z","timestamp":1788415996343,"version":"build-2803163510"},"reference-count":75,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Opioid use disorder (OUD) remains a major public health crisis despite evidence-based medications, including methadone, buprenorphine, and naltrexone. Persistent challenges with treatment retention, access, stigma, and incomplete response highlight the need for adjunctive pharmacotherapies targeting neurobiological systems beyond the mu-opioid receptor.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a narrative review of emerging pharmacologic approaches for OUD and opioid withdrawal syndrome, focusing on ketamine and NMDA receptor antagonists, cannabinoids, psychedelics, and incretin-based therapies, including glucagon-like peptide-1 receptor agonists and dual glucose-dependent insulinotropic polypeptide\/glucagon-like peptide-1 receptor agonists.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Ketamine has preliminary randomized evidence suggesting potential effects on abstinence, withdrawal, craving, and psychotherapy augmentation. Cannabidiol may reduce cue-induced craving and anxiety, whereas dronabinol may modestly suppress opioid withdrawal symptoms. Psychedelic research, particularly involving ibogaine, shows observational signals for withdrawal reduction and abstinence but is limited by safety concerns, regulatory barriers, and sparse controlled evidence. Incretin-based therapies have generated strong observational signals linking GLP-1\u2013based treatment to reduced overdose and OUD-related outcomes, though prospective trials remain limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Across these therapeutic classes, convergent mechanisms include modulation of mesolimbic reward circuitry, cue-reactivity, stress responsivity, neuroplasticity, and cognitive flexibility. Future studies should prioritize rigorous blinding assessment, active comparators, objective endpoints, standardized cue-reactivity measures, diverse samples, and careful safety monitoring. Regulatory policies should facilitate the development and implementation of future research in novel therapies for OUD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fpsyt.2026.1909149","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T05:21:34Z","timestamp":1788412894000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Novel pharmacotherapies for opioid use disorder and opioid withdrawal"],"prefix":"10.3389","volume":"17","author":[{"given":"Mary R.","family":"Shen","sequence":"first","affiliation":[{"name":"Department of Psychiatry, Brigham and Women\u2019s Hospital, Harvard Medical School","place":["Boston, MA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwadwo","family":"Owusu-Boaitey","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Brigham and Women\u2019s Hospital, Harvard Medical School","place":["Boston, MA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zackari D.","family":"Murphy","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Brigham and Women\u2019s Hospital, Harvard Medical School","place":["Boston, MA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex N.","family":"Rains","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Brigham and Women\u2019s Hospital, Harvard Medical School","place":["Boston, MA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip R.","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Brigham and Women\u2019s Hospital, Harvard Medical School","place":["Boston, MA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis W.","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Brigham and Women\u2019s Hospital, Harvard Medical School","place":["Boston, MA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joji","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Brigham and Women\u2019s Hospital, Harvard Medical School","place":["Boston, MA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1017\/S2045796025100085","article-title":"Global, regional, and national trends and burden of opioid use disorder in individuals aged 15 years and above: 1990 to 2021 and projections to 2040","volume":"34","author":"Wang","year":"2025","journal-title":"Epidemiol Psychiatr Sci"},{"key":"B2","unstructured":"Drug overdose deaths in the United States, 2003\u20132023\n          \n          \n            \n              Garnett\n              MF\n            \n            \n              Mini\u00f1o\n              AM\n            \n          \n          Centers for Disease Control and Prevention (U.s.)\n          \n          2024"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.20230273","article-title":"Fentanyl and other opioid use disorders: Treatment and research needs","volume":"180","author":"Volkow","year":"2023","journal-title":"AJP"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.16954","article-title":"Buprenorphine\/Naloxone vs methadone for the treatment of opioid use disorder","volume":"332","author":"Nosyk","year":"2024","journal-title":"JAMA"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-017-3993-2","article-title":"Emergency department-initiated buprenorphine for opioid dependence with continuation in primary care: Outcomes during and after intervention","volume":"32","author":"D\u2019Onofrio","year":"2017","journal-title":"J Gen Intern Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1111\/j.1360-0443.2006.01369.x","article-title":"Efficacy of maintenance treatment with naltrexone for opioid dependence: A meta-analytical review","volume":"101","author":"Johansson","year":"2006","journal-title":"Addiction"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00391-3","article-title":"The opioid crisis and HIV in the USA: Deadly synergies","volume":"397","author":"Hodder","year":"2021","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-020-06257-4","article-title":"Barriers and facilitators to the use of medications for opioid use disorder: A rapid review","volume":"35","author":"Mackey","year":"2020","journal-title":"J Gen Intern Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2017.07.001","article-title":"Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population","volume":"85","author":"Morgan","year":"2018","journal-title":"J Subst Abuse Treat"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(16)00104-8","article-title":"Neurobiology of addiction: A neurocircuitry analysis","volume":"3","author":"Koob","year":"2016","journal-title":"Lancet Psychiatry"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/nrn3119","article-title":"Dysfunction of the prefrontal cortex in addiction: Neuroimaging findings and clinical implications","volume":"12","author":"Goldstein","year":"2011","journal-title":"Nat Rev Neurosci"},{"key":"B12","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/s41398-023-02451-0","article-title":"Rapid neuroplasticity changes and response to intravenous ketamine: A randomized controlled trial in treatment-resistant depression","volume":"13","author":"Kopelman","year":"2023","journal-title":"Transl Psychiatry"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2025.1552084","article-title":"Ketamine in treating opioid use disorder and opioid withdrawal: A scoping review","volume":"16","author":"Shen","year":"2025","journal-title":"Front Psychiatry"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2018.18020138","article-title":"Attenuation of antidepressant effects of ketamine by opioid receptor antagonism","volume":"175","author":"Williams","year":"2018","journal-title":"Am J Psychiatry"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1124\/molpharm.124.000947","article-title":"Ketamine and major ketamine metabolites function as allosteric modulators of opioid receptors","volume":"106","author":"Gomes","year":"2024","journal-title":"Mol Pharmacol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41594-026-01839-y","article-title":"Structural basis of opioid receptor activation by PCP and ketamine","author":"Jiang","year":"2026","journal-title":"Nat Struct Mol Biol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600710516","article-title":"Bioavailability, pharmacokinetics, and analgesic activity of ketamine in humans","volume":"71","author":"Clements","year":"1982","journal-title":"J Pharm Sci"},{"key":"B18","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1002\/bdd.336","article-title":"Plasma concentration profiles of ketamine and norketamine after administration of various ketamine preparations to healthy Japanese volunteers","volume":"24","author":"Yanagihara","year":"2003","journal-title":"Biopharm Drug Dispos"},{"key":"B19","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1080\/02791072.2023.2248989","article-title":"Therapeutic protocols using ketamine and esketamine for depressive disorders: A systematic review","volume":"56","author":"K. Freind","year":"2024","journal-title":"J Psychoact Drugs"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/S0740-5472(02)00275-1","article-title":"Ketamine psychotherapy for heroin addiction: Immediate effects and two-year follow-up","volume":"23","author":"Krupitsky","year":"2002","journal-title":"J Subst Abuse Treat"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1080\/02791072.2007.10399860","article-title":"Single versus repeated sessions of ketamine-assisted psychotherapy for people with heroin dependence","volume":"39","author":"Krupitsky","year":"2007","journal-title":"J Psychoact Drugs"},{"key":"B22","article-title":"Effects of ketamine on precipitated opiate withdrawal","volume":"42","author":"Jovaisa","year":"2006","journal-title":"Med (Kaunas)"},{"key":"B23","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s13063-025-08836-4","article-title":"Adjunctive ketamine vs. buprenorphine in co-occurring major depressive disorder and opioid use disorder: A randomized, double-blind clinical trial assessing anxiety symptom severity and craving intensity","volume":"26","author":"Mansoori","year":"2025","journal-title":"Trials"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/s44220-026-00625-5","article-title":"Ketamine-assisted mindfulness-oriented recovery enhancement for opioid use disorder: A randomized controlled trial","volume":"4","author":"Garland","year":"2026","journal-title":"Nat Ment Health"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2022.2066651","article-title":"Long-term safety of ketamine and esketamine in treatment of depression","volume":"21","author":"Nikayin","year":"2022","journal-title":"Expert Opin Drug Saf"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-020-0793-6","article-title":"Chronic administration of ketamine induces cognitive deterioration by restraining synaptic signaling","volume":"26","author":"Luo","year":"2021","journal-title":"Mol Psychiatry"},{"key":"B27","unstructured":"SPRAVATO\u00ae REMS (Risk Evaluation and Mitigation Strategy)"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1080\/00952990.2025.2541212","article-title":"Ketamine to enhance methadone treatment retention in patients with opioid use disorder and co-morbid depression","volume":"51","author":"Manza","year":"2025","journal-title":"Am J Drug Alcohol Abuse"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/s11481-018-9782-9","article-title":"Cannabis addiction and the brain: A review","volume":"13","author":"Zehra","year":"2018","journal-title":"J Neuroimmune Pharmacol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.drugalcdep.2015.05.013","article-title":"The effects of dronabinol during detoxification and the initiation of treatment with extended release naltrexone","volume":"154","author":"Bisaga","year":"2015","journal-title":"Drug Alcohol Depend"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2016.05.002","article-title":"Opioid withdrawal suppression efficacy of oral dronabinol in opioid dependent humans","volume":"164","author":"Lofwall","year":"2016","journal-title":"Drug Alcohol Depend"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2022.12.022","article-title":"THC and CBD: Similarities and differences between siblings","volume":"111","author":"Stella","year":"2023","journal-title":"Neuron"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1111\/bph.13250","article-title":"Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor","volume":"172","author":"Laprairie","year":"2015","journal-title":"Br J Pharmacol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-006-0033-x","article-title":"Cannabidiol is an allosteric modulator at mu- and delta-opioid receptors","volume":"372","author":"Kathmann","year":"2006","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2019.18101191","article-title":"Cannabidiol for the reduction of cue-induced craving and anxiety in drug-abstinent individuals with heroin use disorder: A double-blind randomized placebo-controlled trial","volume":"176","author":"Hurd","year":"2019","journal-title":"Am J Psychiatry"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2023.1155984","article-title":"Impact of cannabidiol on reward- and stress-related neurocognitive processes among individuals with opioid use disorder: A pilot, double-blind, placebo-controlled, randomized cross-over trial","volume":"14","author":"Suzuki","year":"2023","journal-title":"Front Psychiatry"},{"key":"B37","unstructured":"Adjunctive Cannabidiol for Recovery From Opioid Study (ACROS) [Clinical trial registration\n          \n          \n            \n              Hurd\n              Y\n            \n          \n          Clinicaltrials.Gov\n          \n          2025"},{"key":"B38","unstructured":"Cannabidiol in the Treatment of Opioid Use Disorder [Clinical trial registration\n          \n          \n            \n              Hurd\n              Y\n            \n          \n          Clinicaltrials.Gov\n          \n          2024"},{"key":"B39","unstructured":"Epidiolex (Cannabidiol) Oral Solution"},{"key":"B40","unstructured":"Implementation of the agriculture improvement act of 2018\n          \n          Federal Register\n          \n          2020"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-025-03168-w","article-title":"Exploring the therapeutic potential of psychedelics in treating substance use disorders","volume":"30","author":"Li","year":"2025","journal-title":"Mol Psychiatry"},{"key":"B42","unstructured":"Ascending Single\u2010Dose, Double\u2010Blind, Placebo\u2010Controlled Safety Study of Noribogaine in Opioid\u2010Dependent Patients - Glue - 2016 - Clinical Pharmacology in Drug Development - Wiley Online Library"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2025.116446","article-title":"The therapeutic effects of psychedelics for opioid use disorder: A systematic review of clinical studies","volume":"348","author":"Weleff","year":"2025","journal-title":"Psychiatry Res"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1080\/105504999305848","article-title":"Treatment of acute opioid withdrawal with ibogaine","volume":"8","author":"Alper","year":"1999","journal-title":"Am J Addict"},{"key":"B45","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1080\/00952990.2017.1320802","article-title":"Treatment of opioid use disorder with ibogaine: Detoxification and drug use outcomes","volume":"44","author":"Brown","year":"2018","journal-title":"Am J Drug Alcohol Abuse"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.00529","article-title":"Ibogaine detoxification transitions opioid and cocaine abusers between dependence and abstinence: Clinical observations and treatment outcomes","volume":"9","author":"Mash","year":"2018","journal-title":"Front Pharmacol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-3008-z","article-title":"A non-hallucinogenic psychedelic analogue with therapeutic potential","volume":"589","author":"Cameron","year":"2021","journal-title":"Nature"},{"key":"B48","doi-asserted-by":"publisher","first-page":"8118","DOI":"10.1038\/s41467-024-51856-y","article-title":"Oxa-Iboga alkaloids lack cardiac risk and disrupt opioid use in animal models","volume":"15","author":"Havel","year":"2024","journal-title":"Nat Commun"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1038\/s44184-026-00185-7","article-title":"Accelerated recovery using magnesium ibogaine: Characterizing the subjective experience of its rapid healing from neuropsychiatric disorders","volume":"5","author":"Olash","year":"2026","journal-title":"NPJ Ment Health Res"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1973.01750360040005","article-title":"Residential psychedelic (LSD) therapy for the narcotic addict: A controlled study","volume":"28","author":"Savage","year":"1973","journal-title":"Arch Gen Psychiatry"},{"key":"B51","doi-asserted-by":"publisher","first-page":"30","DOI":"10.2174\/15733998113099990003","article-title":"Ayahuasca-assisted therapy for addiction: Results from a preliminary observational study in Canada","volume":"6","author":"Thomas","year":"2013","journal-title":"Curr Drug Abuse Rev"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1089\/psymed.2023.0012","article-title":"Psilocybin for opioid use disorder in two adults stabilized on buprenorphine: A technical report on study modifications and preliminary findings","volume":"1","author":"Nicholas","year":"2023","journal-title":"Psychedelic Med"},{"key":"B53","unstructured":"Accelerating medical treatments for serious mental illness\n          \n          \n            \n              Orders\n              E\n            \n          \n          The White House\n          \n          2026"},{"key":"B54","unstructured":"89(R) SB 2308 - House Committee Report version - Bill Text"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-021-05876-x","article-title":"Serotonin toxicity of serotonergic psychedelics","volume":"239","author":"Malcolm","year":"2022","journal-title":"Psychopharmacology"},{"key":"B56","doi-asserted-by":"publisher","first-page":"499","DOI":"10.3109\/10826088909081832","article-title":"Differential drug use patterns among sexually abused adolescent girls in treatment for chemical dependency","volume":"24","author":"Harrison","year":"1989","journal-title":"Int J Addict"},{"key":"B57","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.metabol.2019.04.014","article-title":"The incretin system in healthy humans: The role of GIP and GLP-1","volume":"96","author":"Holst","year":"2019","journal-title":"Metabolism"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(18)42531-8","article-title":"Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from Guinea pig pancreas","volume":"267","author":"Eng","year":"1992","journal-title":"J Biol Chem"},{"key":"B59","doi-asserted-by":"publisher","first-page":"181","DOI":"10.3389\/fnins.2013.00181","article-title":"The central GLP-1: Implications for food and drug reward","author":"Skibicka","year":"2013","journal-title":"Front Neurosci"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3390\/medsci13030136","article-title":"Mechanisms of GLP-1 in modulating craving and addiction: Neurobiological and translational insights","volume":"13","author":"Amorim Moreira Alves","year":"2025","journal-title":"Med Sci"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1111\/adb.13117","article-title":"Glucagon-like peptide-1 receptor agonist, liraglutide, reduces heroin self-administration and drug-induced reinstatement of heroin-seeking behaviour in rats","volume":"27","author":"Douton","year":"2022","journal-title":"Addict Biol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainresbull.2022.08.022","article-title":"Dose titration with the glucagon-like peptide-1 agonist, liraglutide, reduces cue- and drug-induced heroin seeking in high drug-taking rats","volume":"189","author":"Evans","year":"2022","journal-title":"Brain Res Bull"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1111\/add.16679","article-title":"The association between glucose-dependent insulinotropic polypeptide and\/or glucagon-like peptide-1 receptor agonist prescriptions and substance-related outcomes in patients with opioid and alcohol use disorders: A real-world data analysis","volume":"120","author":"Qeadan","year":"2025","journal-title":"Addiction"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.35247","article-title":"Semaglutide and opioid overdose risk in patients with type 2 diabetes and opioid use disorder","volume":"7","author":"Wang","year":"2024","journal-title":"JAMA Netw Open"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2026.1766770","article-title":"Association between GLP-1 receptor agonist use and substance use disorders among individuals with type 2 diabetes or obesity: A nested case-control study in the All of Us research program","volume":"17","author":"Abegaz","year":"2026","journal-title":"Front Psychiatry"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2025-086886","article-title":"Glucagon-like peptide-1 receptor agonists and risk of substance use disorders among US veterans with type 2 diabetes: Cohort study","volume":"392","author":"Cai","year":"2026","journal-title":"BMJ"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/j.clnu.2025.106571","article-title":"Glucagon-like peptide-1 receptor agonists and Wernicke encephalopathy: A pharmacovigilance study and literature review","volume":"57","author":"Lev","year":"2026","journal-title":"Clin Nutr"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1172\/jci194740","article-title":"The science of safety: Adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications","volume":"136","author":"Jalleh","year":"2026","journal-title":"J Clin Invest"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03412-w","article-title":"Mapping the effectiveness and risks of GLP-1 receptor agonists","volume":"31","author":"Xie","year":"2025","journal-title":"Nat Med"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1111\/adb.12977","article-title":"The role of withdrawal in mesocorticolimbic drug cue reactivity in opioid use disorder","volume":"26","author":"Shi","year":"2021","journal-title":"Addict Biol"},{"key":"B71","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1177\/0269881116667709","article-title":"Subanesthetic ketamine decreases the incentive-motivational value of reward-related cues","volume":"31","author":"Fitzpatrick","year":"2017","journal-title":"J Psychopharmacol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2021.08.003","article-title":"Neuroplasticity as a convergent mechanism of ketamine and classical psychedelics","volume":"42","author":"Aleksandrova","year":"2021","journal-title":"Trends Pharmacol Sci"},{"key":"B73","unstructured":"Accelerating medical treatments for serious mental illness\n          \n          \n            \n              Orders\n              E\n            \n          \n          The White House\n          \n          2026"},{"key":"B74","unstructured":"American Psychiatric Association Responds to Executive Order on Accelerating Medical Treatments for"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1159\/000069738","article-title":"The problem of the placebo response in clinical trials for psychiatric disorders: Culprits, possible remedies, and a novel study design approach","volume":"72","author":"Fava","year":"2003","journal-title":"Psychother Psychosom"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2026.1909149\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T05:21:35Z","timestamp":1788412895000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2026.1909149\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,3]]},"references-count":75,"alternative-id":["10.3389\/fpsyt.2026.1909149"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2026.1909149","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,3]]},"article-number":"1909149"}}